Dr. Michael Mauro on Treatment Discontinuation for CML

Name: Dr. Michael Mauro on Treatment Discontinuation for CML
Uploaded: 2015-02-20T08:12:00.000Z
Description: Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia.

February 20, 2015

Michael Mauro, MD

Video

Conference|PER® Congress on Hematologic Malignancies (Winter Hematology®)

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia.

Michael Mauro, MD

discusses treatment discontinuation for patients with chronic myeloid leukemia (CML)

hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, .

TKI

Treatment with a can offer a “functional cure,” for some CML patients, aid Mauro. After a period of treatment, some patients may be able to discontinue TKI therapy.

If patients have a good response to therapy without any degree of relapse, lower-risk disease at presentation, and a period of time in a deep molecular remission, they may be a candidate for treatment discontinuation. On average about half of the patients that fit that criteria may be able to stop TKI therepy without having significant relapse.

<<<